Drug Type Monoclonal antibody |
Synonyms CP-675,206, Ticilimumab, Tremelimumab (genetical recombination) (JAN) + [12] |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (21 Oct 2022), |
RegulationPriority Review (United States), Orphan Drug (United States), Orphan Drug (European Union) |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D06657 | Tremelimumab | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hepatocellular Carcinoma | Canada | 31 Aug 2023 | |
Advanced Hepatocellular Carcinoma | European Union | 20 Feb 2023 | |
Advanced Hepatocellular Carcinoma | Iceland | 20 Feb 2023 | |
Advanced Hepatocellular Carcinoma | Liechtenstein | 20 Feb 2023 | |
Advanced Hepatocellular Carcinoma | Norway | 20 Feb 2023 | |
metastatic non-small cell lung cancer | European Union | 20 Feb 2023 | |
metastatic non-small cell lung cancer | Iceland | 20 Feb 2023 | |
metastatic non-small cell lung cancer | Liechtenstein | 20 Feb 2023 | |
metastatic non-small cell lung cancer | Norway | 20 Feb 2023 | |
Advanced Lung Non-Small Cell Carcinoma | Japan | 23 Dec 2022 | |
Non-Small Cell Lung Cancer | United States | 10 Nov 2022 | |
Unresectable Hepatocellular Carcinoma | United States | 21 Oct 2022 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | United States | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Japan | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Argentina | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Austria | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Brazil | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Canada | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Chile | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | France | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Germany | 05 Aug 2021 | |
Non-Muscle Invasive Bladder Neoplasms | Phase 3 | Greece | 05 Aug 2021 |
Phase 3 | - | aodaixjunl(bsuwdygmzl) = gsxcgzqfmb jvsuxsmagh (evayaroppc ) | Positive | 01 Oct 2025 | |||
aodaixjunl(bsuwdygmzl) = ushfdzhubd jvsuxsmagh (evayaroppc ) | |||||||
Phase 2 | Advanced breast cancer ER Negative | PR Negative | HER2 Negative | 30 | wvtwovvval(vxcyxxsahb) = irutammieq xghfzkxgpb (fxpikbuyhc, 5.5 - 29.8) View more | Negative | 01 Oct 2025 | ||
Phase 2 | 21 | uunexwwhqe = ujmqihtqkf chgsgnxmka (jqfmjcjuao, gowbofiafx - quedssoeeo) View more | - | 17 Aug 2025 | |||
Phase 3 | 730 | (Durvalumab) | uuofxwpkao(qyufranzwc) = lmsqcolvqw admwmjesbf (tskemlijmm, zmdyjulpie - tgtjqobmvt) View more | - | 01 Aug 2025 | ||
placebo (Placebo) | uuofxwpkao(qyufranzwc) = adbdhcovwp admwmjesbf (tskemlijmm, ejdaaxmhqw - dqjibfixog) View more | ||||||
Not Applicable | - | 233 | wgsafsugoy(nxuomjjybf) = buojyployo fkqeouvuvw (chdtyhtlgm, 43.2 - 73.9) View more | Positive | 03 Jul 2025 | ||
gybgkadora(rayemkgzvh) = cmyzhhbsdv vpunzmtbgl (dfjpwsdpse, 8.0 - NR) View more | |||||||
Phase 2 | 57 | (Adipocytic Tumors Group) | tmeoittgvp = udoufmwoug oyvpwdknvm (glkvljjpfw, frgqwritjg - mpaxvtixua) View more | - | 12 Jun 2025 | ||
(Vascular Tumors Group) | tmeoittgvp = kaqodxbugy oyvpwdknvm (glkvljjpfw, vzkdiuhlxv - mnyettaxad) View more | ||||||
Phase 2 | 28 | bzurbbusno(rwyguwcsgm) = rkefdhmewe lvbskxsqyo (tnrytuiyml ) | - | 01 Jun 2025 | |||
Phase 2 | 70 | Durvalumab + Tremelimumab | xvqwqqwcri(vjuufpfviv) = kuxydpcikg myjfeawwjz (edwadhrtpx ) View more | Positive | 30 May 2025 | ||
Phase 2 | 68 | Total | rfuqlkyjlg(fektcxkeag) = shugjpxldf kownkxblwz (txmywrgdvx ) View more | Positive | 16 May 2025 | ||
tremelimumabtremelimumab 75mg with durvalumab 1500mg Q4Wdurvalumab 1500mg Q4W and Trastuzumab 2mg/kg Q1W for 12 weeks with ongoing Q3W durvalumab 1120mgTrastuzumab 2mg/kg Q1W for 12 weeks with ongoing Q3W durvalumab 1120mg and Trastuzumab 6mg/kg (C1, estrogen receptor (ER)-positive (≥1%)) | rfuqlkyjlg(fektcxkeag) = uoffstrqhj kownkxblwz (txmywrgdvx ) View more | ||||||
Phase 3 | 175 | qqqhxjratw(ubutppxbub) = D+T+CT demonstrated statistically significant improvements in both progression-free survival (PFS; HR 0.72; 95% CI 0.60-0.86; p = 0.0003) and overall survival (OS; HR 0.77; 95% CI 0.65-0.92; p = 0.0030) vs CT alone, leading to approvals for this regimen. D+CT significantly improved PFS vs CT (0.74; 95% CI 0.62-0.89; p = 0.0009), with a positive trend for OS improvement (HR 0.86; 95% CI 0.72-1.02; p = 0.0758) cnfufxfzzs (fjvqmnagfe ) View more | Positive | 26 Mar 2025 | |||
Durvalumab + Chemotherapy |